Tai‐Tsang Chen

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf, F. Stephen Hodi, Caroline Robert et al. · Journal of Clinical Oncology · 2015 · 2.1K citations · Full text

Medicine, Biostatistics, Oncology +17

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +15

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Michele Maio, Jean‐Jacques Grob, Steinar Aamdal et al. · Journal of Clinical Oncology · 2015 · 471 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen et al. · Annals of Oncology · 2013 · 218 citations

Medicine, Oncology, Pharmacology +13